Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006227 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00006227 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 31 participants.
The verdict
NCT00006227, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This phase II trial studies the effectiveness of paclitaxel in treating patients who have ovarian stromal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Interventions
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2000-11-20 |
| Est. Completion | 2016-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006227
The ClinicalTrials.gov registry entry for NCT00006227 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel is the first listed.
NCT00006227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006227 about?
NCT00006227 is a clinical study titled "Paclitaxel in Treating Patients With Ovarian Stromal Cancer". This phase II trial studies the effectiveness of paclitaxel in treating patients who have ovarian stromal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00006227?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2000-11-20. Estimated completion is 2016-07-16.
What interventions are being tested in trial NCT00006227?
The interventions under investigation include: Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00006227?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.